Altered fractionation radiotherapy in lung cancer

Mauro Palazzi, Annamaria Cerrotta, Sergio Villa

Research output: Contribution to journalArticle

Abstract

Clinical trials on altered fractionation radiotherapy (RT) regimens currently play a significant role in lung cancer, due to the importance of local control and to the disappointing therapeutic results in this disease. In non-small-cell lung cancer (NSCLC) two strategies are being actively investigated: hyperfractionation with a 'curative' aim, and hypofractionation with a palliative aim; in small-cell lung cancer (SCLC) altered fractionation seems to play a minor role at this moment. In this review paper the results of reported randomised trials are summarised and discussed. Conclusions may indicate that through hyperfractionation, particularly if accelerated, clinical outcome of non-metastatic NSCLC patients can be improved; data are however not sufficiently mature to advise its use outside controlled clinical trials. In the palliative setting, hypofractionation should be considered standard treatment.

Original languageEnglish
Pages (from-to)171-175
Number of pages5
JournalTumori
Volume84
Issue number2
Publication statusPublished - Mar 1998

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Radiotherapy
Small Cell Lung Carcinoma
Controlled Clinical Trials
Clinical Trials
Therapeutics

Keywords

  • Altered fractionation
  • Lung Cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Palazzi, M., Cerrotta, A., & Villa, S. (1998). Altered fractionation radiotherapy in lung cancer. Tumori, 84(2), 171-175.

Altered fractionation radiotherapy in lung cancer. / Palazzi, Mauro; Cerrotta, Annamaria; Villa, Sergio.

In: Tumori, Vol. 84, No. 2, 03.1998, p. 171-175.

Research output: Contribution to journalArticle

Palazzi, M, Cerrotta, A & Villa, S 1998, 'Altered fractionation radiotherapy in lung cancer', Tumori, vol. 84, no. 2, pp. 171-175.
Palazzi M, Cerrotta A, Villa S. Altered fractionation radiotherapy in lung cancer. Tumori. 1998 Mar;84(2):171-175.
Palazzi, Mauro ; Cerrotta, Annamaria ; Villa, Sergio. / Altered fractionation radiotherapy in lung cancer. In: Tumori. 1998 ; Vol. 84, No. 2. pp. 171-175.
@article{fe2a8eea1a0c4222b20bbc7265d9179a,
title = "Altered fractionation radiotherapy in lung cancer",
abstract = "Clinical trials on altered fractionation radiotherapy (RT) regimens currently play a significant role in lung cancer, due to the importance of local control and to the disappointing therapeutic results in this disease. In non-small-cell lung cancer (NSCLC) two strategies are being actively investigated: hyperfractionation with a 'curative' aim, and hypofractionation with a palliative aim; in small-cell lung cancer (SCLC) altered fractionation seems to play a minor role at this moment. In this review paper the results of reported randomised trials are summarised and discussed. Conclusions may indicate that through hyperfractionation, particularly if accelerated, clinical outcome of non-metastatic NSCLC patients can be improved; data are however not sufficiently mature to advise its use outside controlled clinical trials. In the palliative setting, hypofractionation should be considered standard treatment.",
keywords = "Altered fractionation, Lung Cancer, Radiotherapy",
author = "Mauro Palazzi and Annamaria Cerrotta and Sergio Villa",
year = "1998",
month = "3",
language = "English",
volume = "84",
pages = "171--175",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Altered fractionation radiotherapy in lung cancer

AU - Palazzi, Mauro

AU - Cerrotta, Annamaria

AU - Villa, Sergio

PY - 1998/3

Y1 - 1998/3

N2 - Clinical trials on altered fractionation radiotherapy (RT) regimens currently play a significant role in lung cancer, due to the importance of local control and to the disappointing therapeutic results in this disease. In non-small-cell lung cancer (NSCLC) two strategies are being actively investigated: hyperfractionation with a 'curative' aim, and hypofractionation with a palliative aim; in small-cell lung cancer (SCLC) altered fractionation seems to play a minor role at this moment. In this review paper the results of reported randomised trials are summarised and discussed. Conclusions may indicate that through hyperfractionation, particularly if accelerated, clinical outcome of non-metastatic NSCLC patients can be improved; data are however not sufficiently mature to advise its use outside controlled clinical trials. In the palliative setting, hypofractionation should be considered standard treatment.

AB - Clinical trials on altered fractionation radiotherapy (RT) regimens currently play a significant role in lung cancer, due to the importance of local control and to the disappointing therapeutic results in this disease. In non-small-cell lung cancer (NSCLC) two strategies are being actively investigated: hyperfractionation with a 'curative' aim, and hypofractionation with a palliative aim; in small-cell lung cancer (SCLC) altered fractionation seems to play a minor role at this moment. In this review paper the results of reported randomised trials are summarised and discussed. Conclusions may indicate that through hyperfractionation, particularly if accelerated, clinical outcome of non-metastatic NSCLC patients can be improved; data are however not sufficiently mature to advise its use outside controlled clinical trials. In the palliative setting, hypofractionation should be considered standard treatment.

KW - Altered fractionation

KW - Lung Cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0031750740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031750740&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 171

EP - 175

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -